Mr.Allen has 30 years of experience in business and finance, including 16 years in executive leadership positions with technology and med-tech businesses. In 1998 Mr. Allen co-founded Regeneration Technologies, Inc. (Nasdaq:RTIX), developing the company's strategic business plan, negotiating the spin-off of the company’s underlying technology from the University of Florida, raising the initial venture capital, and leading its initial public offering in 2000.
Mr. Allen is also the founder of Synogen, a private venture fund investing in early-stage biomedical and medical device companies, and co-founder of Emergent Growth Fund, an angel investment fund. With a background in technology, business and finance, he has had responsibility for finance, business development, IT, HR, IR, technology licensing and M&A, and has negotiated several acquisitions as well as venture capital funding for several successful start-ups. He is also co-founder and director of Sustainable Cambodia, a 501(c)(3) nonprofit organization working to create a sustainable quality of life in Cambodian villages.
Dr. Wohltjen focuses on applying the latest advances in microsensor technologies to the analysis of exhaled breath as a diagnostic matrix. Trained as both an electrical engineer and a chemist, Dr. Wohltjen has been actively engaged in the development and commercialization of novel chemical sensing devices and systems since 1976. In the 1980's he formed the Chemical Microsensor research group at the US Naval Research Lab that pioneered a number of important advances in chemical sensor technology. Later he founded Microsensor Systems, Inc. (MSI) and led the commercial development of Surface Acoustic Wave (SAW) microsensors for detecting chemical warfare threats.
Over the years Dr. Wohltjen has been the principal investigator on more than $10M of federally funded sensor R&D programs. In 1995 his company, MSI, was recognized with the Tibbetts Award from the US Small Business Administration for its successful participation in numerous SBIR programs. Presently Dr. Wohltjen also serves as a director on several boards of academic institutions and small technology-focused companies.
John Harper is an active private equity investor and on the Executive Committee of SpringBoard Capital Partners II. He was the Entrepreneur in Residence at The Innovation Factory, a medical device incubator until January 1, 2006. Previously, he was President and Chief Executive Officer of ATI Medical, a company specializing in the treatment of cancer. Prior to that he was Executive Chairman of Meretekdiagnostics, inc. a company specializing in diagnostic breath tests using isotope labeled substrates to identify disease in the body. Meretek merged with Diasorin a division of American Standard Companies. Previously Mr. Harper was President and Chief Executive Officer of Índigo Medical, Inc. a medical laser company specializing in the minimally invasive treatment of BPH. Mr. Harper successfully merged Índigo with Ethicon EndoSurgery a division of Johnson & Johnson. Prior to joining Índigo Medical, Mr. Harper was President and Chief Executive Officer of Menlo Care, Inc. a manufacturer of specialty vascular access and urology devices. Mr. Harper completed a merger between Menlo Care and Johnson & Johnson Medical a division of Johnson & Johnson. Previously, Mr. Harper managed his own investment business that resulted in the creation of three companies, one was sold to a private investment group, one to a publicly NASDAQ traded company and one sold to a publicly NYSE traded company. Prior, Mr. Harper spent 11 years with Physio Control a cardiac monitor and defibrillation company in sales management. Mr. Harper received his Bachelor of Arts in Economics from Davidson College in 1971.
Dr. Gold has combined academic achievement with business and management expertise in a successful career in medicine, academics and finance. He is currently serving as Dizney Eminent Scholar and Distinguished Professor at the University of Florida College of Medicine's Brain Institute in the Departments of Psychiatry, Neuroscience, Anesthesiology, Community Health & Family Medicine, where he is also Interim Chair and Chief in the Division of Addiction Medicine.
Over his 35 year translational research career, Dr. Gold has done extensive laboratory and clinical research with drugs of abuse, medications, adherence and monitoring. In the field of medical technology, he is a co-inventor of technology for testing of medication Dr. Gold and his Yale colleagues pioneered and automated cocaine testing in blood and urine as well as for other drugs of abuse. adherence and compliance, and therapeutic drug monitoring for medication used to treat epilepsy and other medical conditions. Dr Gold has had considerable experience and success in developing laboratory models for addictions and then developing new treatments. He is one of a very few researchers to have patented important new uses for existing medications without a university as a co-inventor or owner of the patent, and to have then sold the patent to a major multinational pharmaceutical company for manufacture and marketing.
Dr. Gold combines his medical knowledge with many years of experience in business and finance, where he has consulted for companies such as Medtronic, Ciba-Geigy, Merck, Wyeth, Roche, Alkermes, Dupont, Glaxo, Abbott, and Forest Laboratories. He was a major investor and founding member for Aklaim Video, the company responsible for the leading video game Mortal Kombat. He was a co-founder and founding director of Somerset Valley Bank, helping the bank go from concept to its first bank opening, to a chain, to its public listing on NASDAQ and to its sale for nearly $100 million. Dr. Gold has provided consulting services to top-tier financial firms such as Goldman Sachs, Lehman Brothers, Oppenheimer, the Carlyle Group and Smith Barney, as well as currently co-authoring a subscription financial newsletter for Phillips.
As a world-renowned addiction researcher, Dr. Gold has been involved in the development of numerous new approaches which have rapidly progressed from bench-to-bedside. His research has led to changes in the treatment of physician addiction, opiate and cocaine addiction and food addiction. He is the author of twelve professional books and over 900 medical articles, chapters, and abstracts in journals for health professionals. He is frequently the expert interviewed for comment by the Wall Street Journal ,other major business, and national publications concerned with the strengths and limitations of new technology and treatments in obesity, pain, drug addiction and psychiatry.
David Dizney is currently President and Chief Executive Officer of United Medical Corporation. Founded in 1974, United Medical is one of Florida’s largest privately held corporations, which owns and operates a network of hospitals through two operating divisions based out of Windermere, Florida. Ten Broeck operates hospitals and provides management services for client hospitals specializing in acute care and behavioral services. Mr. Dizney is responsible for all operations and strategic planning.
Mr. Dizney’s diverse background in the healthcare industry spans 20 years and includes hospital operations, acquisitions, divestitures and experience in accessing credit markets including bond issuances, private equity and syndicated loans. He oversees a corporate office staff that provides central support and oversight with expertise in regulatory compliance, clinical oversight, managed care contracting, all additional third party reimbursement issues, marketing, internal auditing, and financial reporting. Mr. Dizney has been involved in numerous start-up operations and acquisitions specifically in specialty areas of healthcare delivery including reference lab development, health maintenance organizations, home health agencies, physician practices, and contract management services.
Mr. Dizney serves on the Board of Directors of United Medical Corporation, PaviaHealth Holding Company, Inc. (specialty hospitals serving the Caribbean), the Healthy Florida Foundation and Independent Banc Shares. He represents the companies with the Federation of American Hospitals and serves as the Treasurer for the National Association of Psychiatric Health Systems. A graduate of the University of South Florida with a BS in Finance, Mr. Dizney holds an MBA from the Kellogg School of Management at Northwestern University.
Mr. Johnson is an original investor and founding Board member of Xhale, Inc. He is a member of the family that founded Johnson and Johnson (NYSE:JNJ), and remains interested in translational, medical research and innovation. Both a philanthropist and businessman who has distinguished himself in local, regional and national start ups, Mr. Johnson was a founder of the Somerset Valley Bank, a one-location bank started in a remodeled house in the County seat near the Johnson family home in New Jersey. From these humble beginnings, the bank grew to a regional chain, financial service firm, NASDAQ listing, and ultimately purchase by Fulton Financial. Mr. Johnson remained active on the BOD and Committees for over a decade. He is a Florida resident who serves on the Board of Directors of the Benjamin School. Mr. Johnson regularly evaluates new technology and treatments when visiting the University of Florida. He helped fund the UF start up Viewray, a novel radiation oncology company formed after a McKnight Brain Institute scientific discovery and patent. Viewray has since moved from Gainesville to Cleveland and has received major investments from Orbimed, Fidelity and the State of Ohio as it prepares to bring its novel approach to cancer treatment to market this year.